Retisert: Is the new advance in treatment of uveitis a good one?

Annals of Pharmacotherapy

Volumn 41, Issue 3, 2007, Pages 449-455

  Mohammad, Dina A ^a   Sweet, Burgunda V ^a,b,d   Elner, Susan G ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b Drug Information and Investigational Drug Services   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Fluocinolone acetonide; Intravitreal implant; Ocular steroids; Uveitis

Indexed keywords

ADALIMUMAB; ALKYLATING AGENT; ANTIMETABOLITE; CORTICOSTEROID; FLUOCINOLONE ACETONIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABNORMAL SENSATION; ADRENAL SUPPRESSION; BLURRED VISION; BONE MARROW SUPPRESSION; CATARACT; CLINICAL TRIAL; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EXTRAOCULAR MUSCLE; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; GLAUCOMA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IMPLANT; INFECTION RISK; INTRAOCULAR PRESSURE; KIDNEY FAILURE; LIVER FAILURE; MEDLINE; NONHUMAN; OSTEOPOROSIS; PERFORATING EYE INJURY; PRIORITY JOURNAL; PSYCHOSIS; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SIDE EFFECT; TEAR FLOW; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; FLUOCINOLONE ACETONIDE; HUMANS; TREATMENT OUTCOME; UVEITIS;

EID: 34047216320     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H540     Document Type: Review

References (19)

1. Forster DJ. General approach to the uveitis patient and treatment strategies. In: Yanoff M, Duker JS, eds. Ophthalmology. 2nd ed. St. Louis: Mosby, 2004:1115-20.
2. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 2004;88:1159-62.
3. McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol 1996;121:35-46.
4. Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000;107:2024-33.
5. Retisert (fluocinolone acetonide intravitreal implant) formulary kit. Rochester, NY: Bausch & Lomb, May 2005.
6. Anglade E, Whitcup SM. The diagnosis and management of uveitis. Drugs 1995;49:213-23.
7. The Merck manual of diagnosis and therapy. 17th ed. Whitehouse Station, NJ: Merck & Co., 1999:725-9.
8. Acharya N, Young L. Sustained-release drug implants for the treatment of intraocular disease. Int Ophthalmol Clin 2004;44:33-9.
9. Haupert CL, Jaffe GJ. New and emerging treatments for patients with uveitis. Int Ophthalmol Clin 2000;40:205-20.
10. Package insert. Retisert (fluocinolone acetonide). Rochester, NY: Bausch & Lomb, April 2005.
11. Hainsworth DP, Pearson PA, Conklin JD, Ashton P. Sustained release intravitreal dexamethasone. J Ocul Pharmacol Ther 1996;12:57-63.
12. Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina 2000;20:402-3.
13. Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000;41:3569-75.
14. Driot J, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004;20:269-75.
15. Mruthyunjaya P, Khalatbari D, Yang P, et al. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. Arch Ophthalmol 2006;124:1012-8.
16. Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005;112:1192-8.
17. Jaffe GJ, Martin DM, Callanan D, Pearson A, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-7.
18. Food and Drug Administration. Approval letter for Retisert. www.fda. gov/cder/foi/appletter/2005/021737ltr.pdf (accessed 2006 Aug 30).
19. Drug topics red book. Montvale, NJ: Thomson Healthcare, 2006.